SANN Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About Santhera Pharmaceuticals Holding (SWX: SANN)
›
Santhera Pharmaceuticals Holding (SWX: SANN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 93 employees.
The shares were at 13.64 CHF on 19 November 2026, up 27.7% over 52 weeks. Its 52-week range is 10.12 CHF to 18.84 CHF: the price is 27.6% below the high and 34.8% above the low.
Its market capitalisation is 208.95M CHF.
Santhera Pharmaceuticals Holding reports return on equity of 416.7%, an operating margin of -8.6% and revenue up 101.3% year over year.
It holds more cash than debt, a net cash position of 494.00K CHF. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 27.50 CHF is 101.6% above the current price.